The identification of TNBC-specific antigens such as ROR1 and AXL could also lead to an efficient CAR-NK therapy approach to treat TNBC, similar to CD19 CAR-T for pre-B ALL treatment. The gene discussed is AXL; the disease is acute lymphoblastic leukemia.